| Company | Offering Month | Offering Price | 2000 Close | % Change |
| Aviron Inc. | April | $22.50 | $66.81 | 197% |
| Albany Molecular Research Inc. | October | $42.25 | $61.63 | 46% |
| ArQule Inc. | November | $22.50 | $32 | 42% |
| ICOS Corp. | December | $37 | $51.94 | 40% |
| Enzon Inc. | March | $44.50 | $62.06 | 39% |
| Cima Labs Inc. | November | $50 | $65.06 | 30% |
| Cell Therapeutics Inc. | September | $38 | $45.06 | 19% |
| Regeneron Pharmaceuticals Inc. | March | $29.75 | $35.27 | 19% |
| Oxford GlycoSciences plc | December | $18.36 | $21.25 | 16% |
| NPS Pharmaceuticals Inc. | November | $42 | $48 | 14% |
| OSI Pharmaceuticals Inc. | November | $70 | $80.13 | 14% |
| Abgenix Inc. | February | $52.50 | $59.06 | 13% |
| Neurocrine Biosciences Inc. | December | $30 | $33.13 | 10% |
| Bone Care International Inc. | December | $16 | $17.31 | 8% |
| NeoPharm Inc. | September | $35.50 | $37.88 | 7% |
| IDEC Pharmaceuticals Corp. | November | $181.10 | $189.56 | 5% |
| Neose Technologies Inc. | March | $32 | $33 | 3% |
| Immunex Corp. | November | $39.75 | $40.63 | 2% |
| Genentech Inc. | March | $81.50 | $81.50 | 0% |
| Onyx Pharmaceuticals Inc. | October | $15 | $14.88 | -1% |
| Visible Genetics Inc. | March | $38 | $37.75 | -1% |
| Millennium Pharmaceuticals Inc. | October | $64 | $61.88 | -3% |
| Celgene Corp. | February | $33.67 | $32.50 | -3% |
| Dendreon Corp. | October | $15.63 | $15 | -4% |
| Human Genome Sciences Inc. | October | $75 | $69.31 | -8% |
| Aradigm Corp. | March | $16 | $14.63 | -9% |
| Cubist Pharmaceuticals Inc. | April | $33 | $29 | -12% |
| Corixa Corp. | April | $32 | $27.88 | -13% |
| Angiotech Pharmaceuticals Inc. | March | $53.50 | $46 | -14% |
| Tularik Inc. | March | $35.13 | $29.44 | -16% |
| North American Scientific Inc. | December | $17.88 | $14.50 | -19% |
| Avigen Inc. | April | $26 | $20.75 | -20% |
| Ribozyme Pharmaceuticals Inc. | April | $18 | $14.31 | -20% |
| EntreMed Inc. | June | $22 | $17.25 | -22% |
| Protein Design Labs Inc. | September | $118.40 | $86.88 | -27% |
| Corvas International Inc. | November | $20 | $14.38 | -28% |
| Genzyme Transgenics Corp. | February | $20 | $14.31 | -28% |
| Texas Biotechnology Corp. | April | $12.50 | $8.59 | -31% |
| CuraGen Corp. | November | $41 | $27.31 | -33% |
| AVI BioPharma Inc. | July | $7.25 | $4.75 | -34% |
| ImmunoGen Inc. | November | $33 | $21.44 | -35% |
| Biopure Corp. | March | $35 | $20 | -43% |
| Avigen Inc. | November | $37.50 | $20.75 | -45% |
| Vical Inc. | January | $36.50 | $18.50 | -49% |
| Medarex Inc. | March | $86 | $40.75 | -53% |
| Avigen Inc. | November | $45.06 | $20.75 | -54% |
| The Immune Response Corp. | August | $6 | $2.63 | -56% |
| Diacrin Inc. | March | $11.50 | $5 | -57% |
| Emisphere Technologies Inc. | March | $72.75 | $25 | -66% |
| Gene Logic Inc. | January | $56 | $18.38 | -67% |
| SuperGen Inc. | March | $45 | $13.88 | -69% |
| Insmed Inc. | October | $11.88 | $3.47 | -71% |
| Entropin Inc. | March | $7.25 | $2 | -72% |
| Maxygen Inc. | March | $97 | $24.50 | -75% |
| Genome Therapeutics Corp. | July | $31.01 | $6.97 | -78% |
| Celera Genomics | March | $225 | $36.13 | -84% |
| Nanogen Inc. | March | $55 | $9 | -84% |
| Maxim Pharmaceuticals Inc. | February | $55 | $6.38 | -88% |
| Average Change: -16.7% | ||||
